Sangamo Therapeutics, Inc. SGMO Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sangamo Therapeutics, Inc. SGMO

SGMO 0.446

-3.3%

10:15 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Ian@SI	10/17/2006 1:17:34 PM
	Read Replies (1) of 368

12:02PM Sangamo BioSci announces VEGF-A has been demonstrated to have direct neurotrophic and neuroprotective properties in several models (SGMO) 5.37 -0.08 : Co announces the presentation of preclinical data from its ZFP Therapeutic program in nerve regeneration at the 2006 Annual Meeting of The Society for Neuroscience. The co says VEGF-A has been demonstrated to have direct neurotrophic and neuroprotective properties in several models that assess nerve integrity and health. The data presented by Dr. Fehlings demonstrate that treatment of the spinal cord at the time of injury with a VEGF ZFP TF had a statistically significant effect on a number of measures of nerve integrity and health in an animal model of SCI. Dr. Fehlings and his colleagues observed that administration of the ZFP TF resulted in increased levels of the three major isoforms of the VEGF protein that resulted in a neuroprotective effect with a statistically significant decrease in nerve fiber degradation and post-injury nerve cell death. They also noted an increase in blood vessel density around the injury.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next